Ultragenyx Pharmaceutical (RARE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $14.54, -4.15% vs the prior close of $15.17.
- Volume 2.92M shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RARE slides 4.2% to $14.54. Closed at $14.54, -4.15% vs the prior close of $15.17. Day range $14.44–$15.21, opened at $15.21.
RARE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RARE slides 4.2% to $14.54
- Closed at $14.54, -4.15% vs the prior close of $15.17. Day range $14.44–$15.21, opened at $15.21.
- Volume was 2.92M shares, 0.6x its 50-day average of 4.62M.
- Price is -23.6% vs its 50-day average ($19.03) and -37.5% vs its 200-day average ($23.26).
- 52-week range $12.73–$39.89; today's close sits at 7% of that range, 63.5% below the 52-week high.
Oct 15, 2026 — RARE rises 1.8% to $15.17
- Closed at $15.17, +1.81% vs the prior close of $14.90. Day range $14.79–$15.37, opened at $14.87.
- Volume was 3.33M shares, 0.7x its 50-day average of 4.61M.
- Price is -21.2% vs its 50-day average ($19.26) and -34.9% vs its 200-day average ($23.30).
- 52-week range $12.73–$39.89; today's close sits at 9% of that range, 62.0% below the 52-week high.
Oct 14, 2026 — RARE ends flat (-0.1%) to $14.90, 3 down days in a row
- Closed at $14.90, -0.13% vs the prior close of $14.92. Day range $14.67–$15.18, opened at $14.93.
- Volume was 2.95M shares, 0.6x its 50-day average of 4.59M.
- Price is -23.4% vs its 50-day average ($19.45) and -36.1% vs its 200-day average ($23.33).
- 52-week range $12.73–$39.89; today's close sits at 8% of that range, 62.6% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 13, 2026 — RARE dips 2.5% to $14.92
- Closed at $14.92, -2.48% vs the prior close of $15.30. Day range $14.69–$15.39, opened at $15.27.
- Volume was 5.31M shares, 1.2x its 50-day average of 4.53M.
- Price is -24.2% vs its 50-day average ($19.67) and -36.3% vs its 200-day average ($23.42).
- 52-week range $12.73–$39.89; today's close sits at 8% of that range, 62.6% below the 52-week high.
Oct 12, 2026 — RARE dips 1.2% to $15.30
- Closed at $15.30, -1.16% vs the prior close of $15.48. Day range $15.10–$15.49, opened at $15.42.
- Volume was 2.90M shares, 0.6x its 50-day average of 4.50M.
- Price is -23.0% vs its 50-day average ($19.87) and -35.0% vs its 200-day average ($23.52).
- 52-week range $12.73–$39.89; today's close sits at 9% of that range, 61.6% below the 52-week high.
Oct 9, 2026 — RARE rises 1.2% to $15.48, 3 up days in a row
- Closed at $15.48, +1.24% vs the prior close of $15.29. Day range $15.23–$15.73, opened at $15.30.
- Volume was 2.93M shares, 0.7x its 50-day average of 4.49M.
- Price is -22.9% vs its 50-day average ($20.07) and -34.4% vs its 200-day average ($23.61).
- 52-week range $12.73–$39.89; today's close sits at 10% of that range, 61.2% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — RARE rises 2.7% to $15.29
- Closed at $15.29, +2.69% vs the prior close of $14.89. Day range $14.43–$15.52, opened at $14.79.
- Volume was 5.40M shares, 1.2x its 50-day average of 4.43M.
- Price is -24.6% vs its 50-day average ($20.28) and -35.5% vs its 200-day average ($23.71).
- 52-week range $12.73–$39.89; today's close sits at 9% of that range, 61.7% below the 52-week high.
Oct 7, 2026 — RARE rises 3.0% to $14.89
- Closed at $14.89, +2.97% vs the prior close of $14.46. Day range $14.35–$15.25, opened at $14.37.
- Volume was 4.16M shares, 0.9x its 50-day average of 4.39M.
- Price is -27.3% vs its 50-day average ($20.47) and -37.4% vs its 200-day average ($23.80).
- 52-week range $12.73–$39.89; today's close sits at 8% of that range, 62.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — RARE ends flat (-0.3%) to $14.46
- Closed at $14.46, -0.28% vs the prior close of $14.50. Day range $14.08–$14.70, opened at $14.60.
- Volume was 3.89M shares, 0.9x its 50-day average of 4.34M.
- Price is -30.1% vs its 50-day average ($20.69) and -39.5% vs its 200-day average ($23.89).
- 52-week range $12.73–$39.89; today's close sits at 6% of that range, 63.8% below the 52-week high.
Oct 5, 2026 — RARE slides 4.7% to $14.50
- Closed at $14.50, -4.73% vs the prior close of $15.22. Day range $14.21–$15.31, opened at $15.25.
- Volume was 4.66M shares, 1.1x its 50-day average of 4.28M.
- Price is -30.8% vs its 50-day average ($20.94) and -39.5% vs its 200-day average ($23.99).
- 52-week range $12.73–$39.89; today's close sits at 7% of that range, 63.7% below the 52-week high.
Oct 2, 2026 — RARE jumps 3.2% to $15.22
- Closed at $15.22, +3.19% vs the prior close of $14.75. Day range $14.67–$15.28, opened at $14.90.
- Volume was 3.88M shares, 0.9x its 50-day average of 4.24M.
- Price is -28.2% vs its 50-day average ($21.19) and -36.8% vs its 200-day average ($24.09).
- 52-week range $12.73–$39.89; today's close sits at 9% of that range, 61.8% below the 52-week high.
RARE latest news & SEC filings
Every SEC filing by or about RARE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Huizenga Theodore Alan sold 1,283 shares at $13.57 (≈$17.41K) on Sep 15, 2026
- Huizenga Theodore Alan sold 1,283 shares at $13.57 (≈$17.41K) on Sep 15, 2026
- Huizenga Theodore Alan sold 1,283 shares at $13.57 (≈$17.41K) on Sep 15, 2026
- Huizenga Theodore Alan sold 1,283 shares at $13.57 (≈$17.41K) on Sep 15, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Huizenga Theodore Alan sold 161 shares at $13.99 (≈$2.25K) on Sep 3, 2026
- Huizenga Theodore Alan sold 161 shares at $13.99 (≈$2.25K) on Sep 3, 2026
- Huizenga Theodore Alan sold 161 shares at $13.99 (≈$2.25K) on Sep 3, 2026
- Huizenga Theodore Alan sold 161 shares at $13.99 (≈$2.25K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $214.00M (prior year $167.00M) (+28.1% vs Jun 30, 2025)
- Net income: -$92.00M (prior year -$115.00M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.90 (prior year -$1.17) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Parschauer Karah Herdman sold 1,900 shares at $24.92 (≈$47.35K) on Aug 3, 2026
- Parschauer Karah Herdman sold 1,900 shares at $24.92 (≈$47.35K) on Aug 3, 2026
- Parschauer Karah Herdman sold 1,900 shares at $24.92 (≈$47.35K) on Aug 3, 2026
- Parschauer Karah Herdman sold 1,900 shares at $24.92 (≈$47.35K) on Aug 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade RARE
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 12, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.52% (largest 6.6%).
- Liquidity: about 4.43M shares (≈$64.41M) trade per day on average.
- 52-week position: $14.54 vs a range of $12.73–$39.89 (7% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Theodore Alan Huizenga sold 1,283 shares on Sep 15, 2026.
- Latest filings: 8-K Oct 14, 2026; 8-K Oct 7, 2026; 8-K Sep 17, 2026.
- Share count: 98.59M shares outstanding (Jul 31, 2026), +2.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RARE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 15.21 | 15.21 | 14.44 | 14.54 | 2.92M |
| Oct 15, 2026 | 14.87 | 15.37 | 14.79 | 15.17 | 3.33M |
| Oct 14, 2026 | 14.93 | 15.18 | 14.67 | 14.90 | 2.95M |
| Oct 13, 2026 | 15.27 | 15.39 | 14.69 | 14.92 | 5.31M |
| Oct 12, 2026 | 15.42 | 15.49 | 15.10 | 15.30 | 2.90M |
| Oct 9, 2026 | 15.30 | 15.73 | 15.23 | 15.48 | 2.93M |
| Oct 8, 2026 | 14.79 | 15.52 | 14.43 | 15.29 | 5.40M |
| Oct 7, 2026 | 14.37 | 15.25 | 14.35 | 14.89 | 4.16M |
| Oct 6, 2026 | 14.60 | 14.70 | 14.08 | 14.46 | 3.89M |
| Oct 5, 2026 | 15.25 | 15.31 | 14.21 | 14.50 | 4.66M |
| Oct 2, 2026 | 14.90 | 15.28 | 14.67 | 15.22 | 3.88M |
| Oct 1, 2026 | 15.03 | 15.25 | 14.62 | 14.75 | 4.12M |
| Sep 30, 2026 | 15.48 | 15.53 | 14.86 | 15.03 | 4.42M |
| Sep 29, 2026 | 14.45 | 15.50 | 14.11 | 15.32 | 5.88M |
| Sep 28, 2026 | 14.33 | 14.47 | 14.11 | 14.41 | 4.94M |
| Sep 25, 2026 | 14.87 | 14.94 | 14.15 | 14.50 | 4.30M |
| Sep 24, 2026 | 14.73 | 14.87 | 14.55 | 14.77 | 3.49M |
| Sep 23, 2026 | 15.40 | 15.50 | 14.54 | 14.88 | 5.70M |
| Sep 22, 2026 | 14.78 | 16.12 | 14.48 | 15.61 | 8.13M |
| Sep 21, 2026 | 14.58 | 15.01 | 14.27 | 14.65 | 5.27M |
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (RARE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NOVATO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1515673.
RARE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Deborah Dunsire | Director | May 18, 2026 |
| Matthew K Fust | Director | May 18, 2026 |
| Emil D Kakkis | President & CEO | Apr 20, 2026 |
| Michael Narachi | Director | May 18, 2026 |
| Amrit Ray | Director | May 18, 2026 |
| Shehnaaz Suliman | Director | May 18, 2026 |
| Corazon (Corsee) D. Sanders | Director | Jun 15, 2026 |
| Daniel G Welch | Director | May 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Eric Crombez | EVP and Chief Medical Officer | May 6, 2026 |
| Erik Harris | EVP & Chief Commercial Officer | Apr 20, 2026 |
| Howard Horn | Chief Financial Officer | Aug 4, 2026 |
| Dennis Karl Huang | See Remarks | Apr 20, 2026 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sep 15, 2026 |
| Emil D Kakkis | President & CEO | Apr 20, 2026 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | Aug 4, 2026 |
| John Richard Pinion | See Remarks | Apr 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Theodore Alan Huizenga | Sale | 1,283 | $13.57 |
| Sep 15, 2026 | Theodore Alan Huizenga | Sale | 1,283 | $13.57 |
| Sep 15, 2026 | Theodore Alan Huizenga | Sale | 1,283 | $13.57 |
| Sep 15, 2026 | Theodore Alan Huizenga | Sale | 1,283 | $13.57 |
| Sep 3, 2026 | Theodore Alan Huizenga | Sale | 161 | $13.99 |
| Sep 3, 2026 | Theodore Alan Huizenga | Sale | 161 | $13.99 |
| Sep 3, 2026 | Theodore Alan Huizenga | Sale | 161 | $13.99 |
| Sep 3, 2026 | Theodore Alan Huizenga | Sale | 161 | $13.99 |
| Aug 3, 2026 | Karah Herdman Parschauer | Sale | 1,900 | $24.92 |
| Aug 3, 2026 | Karah Herdman Parschauer | Sale | 1,900 | $24.92 |
| Aug 3, 2026 | Karah Herdman Parschauer | Sale | 1,900 | $24.92 |
| Aug 3, 2026 | Karah Herdman Parschauer | Sale | 1,900 | $24.92 |
| Aug 3, 2026 | Howard Horn | Sale | 4,696 | $24.92 |
| Aug 3, 2026 | Howard Horn | Sale | 4,696 | $24.92 |
| Aug 3, 2026 | Howard Horn | Sale | 4,696 | $24.92 |
RARE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $673.00M | $-575.00M | -5.83 | $-466.00M |
| Dec 31, 2024 | $560.00M | $-569.00M | -6.29 | $-414.00M |
| Dec 31, 2023 | $434.00M | $-607.00M | -8.25 | $-475.00M |
| Dec 31, 2022 | $363.33M | $-707.42M | -10.12 | $-380.46M |
| Dec 31, 2021 | $351.41M | $-454.02M | -6.70 | $-338.69M |
Latest balance sheet: total assets $1.26B, total liabilities $1.55B, cash $125.00M (as of Jun 30, 2026).
RARE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $25.81 |
| May 5, 2026 | 8-K Item 2.02 (results) | $25.01 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $23.50 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $24.37 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $32.46 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $28.92 |
| May 6, 2025 | 8-K Item 2.02 (results) | $35.06 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $43.52 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $43.16 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $52.18 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RARE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.